The mainstay therapy of DMD patients is glucocorticoids (prednisone, prednisolone, and deflazacort), which target the glucocorticoid receptor to exert anti-inflammation effects by suppressing the NF-κB signaling pathway [98,99,100]. This evidence concerns the gene NR3C1 and Duchenne muscular dystrophy.